stockrow
Friday 6 November 2026
Export CDNA’s income statement to Excel — free account
CareDx, Inc.
CDNA Healthcare Diagnostics & Research
CareDx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $379.8 million, up 13.8% from fiscal 2024.
- Revenue
- +39.3%
- EPS
- +1,134.0%
- Free cash flow
- −68.6%
Quarter to September 2026, against a year earlier
78.10
1.77
+2.32%
Follow CDNA
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 13.26 | 26.10 |
P/S ratio |
2.64 | 2.15 | 3.20 | 6.81 | |
P/FCF ratio |
29.06 | 14.03 | 17.64 | 58.22 | |
P/Operating CF |
46.99 | 204.94 | 47.93 | 266.36 | |
P/B ratio |
3.31 | 2.83 | 3.45 | 7.25 | |
Price to Tangible BV |
4.35 | 3.68 | 3.95 | 16.45 | |
EV/Sales |
2.18 | 1.70 | 2.39 | 6.31 | |
EV/EBITDA |
0.00 | 118.53 | 8.43 | 22.21 | |
EV/Operating CF |
19.73 | 9.64 | 11.70 | 45.49 | |
EV/FCF |
24.00 | 11.11 | 13.18 | 53.96 | |
Quick Ratio |
2.45 | 2.93 | 4.35 | 2.15 | |
Current Ratio |
2.86 | 3.40 | 4.58 | 2.31 | |
Net Debt/EBITDA |
177.21 | (25.20) | (3.17) | (14.58) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.84 | 0.92 | 0.94 | 0.93 | |
Operating CF/Net income |
(5.20) | 1.54 | 0.28 | 0.66 | |
Capex/Depreciation |
(0.39) | (0.61) | (0.41) | (0.18) | |
Research and Development Expense of Revenue |
17.81% | 18.20% | 16.96% | 15.30% | |
Selling, General and Administrative Expense of Revenue |
55.00% | 51.71% | 56.35% | 49.97% | |
Intangible Assets out of Total Assets |
0.18 | 0.18 | 0.10 | 0.41 | |
Share Based Compensation of Revenue |
7.46% | 8.33% | 8.07% | 6.93% | |
Graham Net Nets |
0.15 | 0.19 | 0.22 | 0.04 | |
Graham Number |
0.00 | 0.00 | 20.00 | 22.42 | |
Earnings Yield |
(2.12%) | (0.92%) | 7.54% | 3.83% | |
Free Cash Flow Yield |
3.44% | 7.13% | 5.67% | 1.72% | |
Revenue per Share |
2.03 | 2.30 | 2.56 | 2.67 | |
Operating CF per Share |
0.40 | 0.08 | 0.59 | 0.24 | |
Capex per Share |
(0.04) | (0.07) | (0.04) | (0.03) | |
Free Cash Flow per Share |
0.36 | 0.01 | 0.56 | 0.21 | |
Cash per Share |
3.33 | 3.66 | 7.26 | 4.81 | |
Shareholders Equity per Share |
5.69 | 6.13 | 8.27 | 8.97 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.69 | 6.13 | 8.27 | 8.97 | |
Free Cash Flow |
19.39 | 0.51 | 28.75 | 11.10 | |
Working Capital |
167.28 | 190.24 | 335.53 | 182.32 | |
Capital Expenditures |
(1.97) | (3.82) | (1.86) | (1.61) | |
Net Current Asset Value |
147.01 | 171.87 | 321.83 | 147.30 | |
EV/EBIT |
0.00 | 0.00 | 10.13 | 26.95 | |
Capex to Sales |
0.02 | 0.03 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 13.57 | 29.08 | |
| Other line items | |||||
Average Receivables |
53.62 | 58.04 | 50.87 | 47.79 | |
Average Payables |
8.84 | 8.57 | 9.68 | 11.20 | |
Average Inventory |
23.10 | 24.67 | 17.45 | 18.74 | |
Average Assets |
452.14 | 450.35 | 488.62 | 536.88 | |
Average Common Equity |
340.77 | 346.44 | 376.48 | 389.30 |
Columns are period end dates · fundamentals updated 6 Nov 2026